We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+4.79%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$9.92B
AUM Growth
+$227M
(+2.3%)
Cap. Flow
-$128M
Cap. Flow
% of AUM
-1.29%
Top 10 Holdings %
Top 10 Hldgs %
23.77%
Holding
295
New
45
Increased
130
Reduced
64
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arch Capital
ACGL
|
+$79.5M |
| 2 |
Intel
INTC
|
+$77.4M |
| 3 |
HCA Healthcare
HCA
|
+$66M |
| 4 |
Altria Group
MO
|
+$62.4M |
| 5 |
Merck
MRK
|
+$53.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$171M |
| 2 |
VR
Validus Hold Ltd
VR
|
+$156M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$76.7M |
| 4 |
UnitedHealth
UNH
|
+$62.8M |
| 5 |
Nektar Therapeutics
NKTR
|
+$60.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.04% |
| 2 | Financials | 22.63% |
| 3 | Healthcare | 19.22% |
| 4 | Communication Services | 10.44% |
| 5 | Industrials | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
AXIS Capital
AXS
$7.81B
| – | – |
-300,000
| Closed | -$15.1M |
|
|
BLUE
252
DELISTED
bluebird bio
BLUE
| – | – |
-1,351
| Closed | -$3.12M |
|
253
Boston Scientific
BSX
$68.4B
| – | – |
-327,000
| Closed | -$8.11M |
|
254
Cigna
CI
$78.4B
| – | – |
-170,000
| Closed | -$34.5M |
|
255
HUTCHMED
HCM
$1.96B
| – | – |
-30,000
| Closed | -$1.15M |
|
256
JELD-WEN Holding
JELD
$110M
| – | – |
-767,729
| Closed | -$30.2M |
|
|
257
Johnson & Johnson
JNJ
$640B
| – | – |
-1,226,752
| Closed | -$171M |
|
258
Labcorp
LH
$25.2B
| – | – |
-238,004
| Closed | -$32.6M |
|
259
Lam Research
LRCX
$316B
| – | – |
-215,100
| Closed | -$3.96M |
|
260
Main Street Capital
MAIN
$5.05B
| – | – |
-99,914
| Closed | -$3.97M |
|
261
Microchip Technology
MCHP
$38.8B
| – | – |
-49,138
| Closed | -$2.16M |
|
|
262
Nektar Therapeutics
NKTR
$2.39B
| – | – |
-67,852
| Closed | -$60.8M |
|
263
Omnicell
OMCL
$1.88B
| – | – |
-540,938
| Closed | -$26.2M |
|
264
Puma Biotechnology
PBYI
$398M
| – | – |
-445,000
| Closed | -$44M |
|
265
Penumbra
PEN
$12.6B
| – | – |
-345,385
| Closed | -$32.5M |
|
266
Protagonist Therapeutics
PTGX
$8.55B
| – | – |
-50,000
| Closed | -$1.04M |
|
|
SEM
267
DELISTED
Select Medical
SEM
| – | – |
-3,292,260
| Closed | -$31.3M |
|
268
Sarepta Therapeutics
SRPT
$1.64B
| – | – |
-25,000
| Closed | -$1.39M |
|
269
TSMC
TSM
$1.94T
| – | – |
-60,228
| Closed | -$2.39M |
|
270
Ziff Davis
ZD
$2B
| – | – |
-49,167
| Closed | -$3.21M |
|
|
XYZ
271
Block Inc
XYZ
$48.9B
| – | – |
-181,313
| Closed | -$6.28M |
|
|
CLDR
272
DELISTED
Cloudera, Inc.
CLDR
| – | – |
-1,537,115
| Closed | -$25.4M |
|
|
IPHI
273
DELISTED
INPHI CORPORATION
IPHI
| – | – |
-88,930
| Closed | -$3.26M |
|
|
PTLA
274
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-588,200
| Closed | -$28.6M |
|
|
RARX
275
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – |
-125,000
| Closed | -$1.06M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q1 2018 Portfolio in Review
As of Q1 2018, Polar Capital held 295 positions worth $9.92B, up 2.3% from $9.69B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Polar Capital's Q1 2018 filing shows 45 new, 130 increased, 64 reduced and 40 closed positions. Its largest new stake was Intel: 1,627,806 shares worth $84.5M. The largest sale was Johnson & Johnson, an estimated $171M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- Polar Capital's largest Q1 2018 buy was Intel: 1,627,806 shares worth $84.5M.
- Polar Capital added most to Arch Capital in Q1 2018, an estimated $79.5M increase.
- Polar Capital's biggest Q1 2018 reduction was Validus Hold Ltd, cutting an estimated $156M.
- Polar Capital fully exited Johnson & Johnson in Q1 2018, selling an estimated $171M.
- Polar Capital's ten largest holdings make up 24% of its $9.92B portfolio in Q1 2018.
- Polar Capital opened 45 new positions and closed 40 in Q1 2018.
- Polar Capital's portfolio value rose 2.3% quarter-over-quarter to $9.92B.
Based on Polar Capital's 13F filing for Q1 2018, filed 15 May 2018.